Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

Haematologica

Volumn 97, Issue 1, 2012, Pages 15-20

  Weiss Smith, Sheila ^a,b   Sato, Masayo ^a   Gore, Steven D ^c   Baer, Maria R ^b,d   Ke, Xuehua ^a   Mcnally, Diane ^a   Davidoff, Amy ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Case crossover; Drug safety; Erythropoiesis stimulating agents; Myelodysplastic syndromes; Thrombosis

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CENTRAL VENOUS CATHETERIZATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA BASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; RISK ASSESSMENT; UNITED STATES;

AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; VENOUS THROMBOSIS;

EID: 84855211855     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051755     Document Type: Article

References (26)

1. Davidoff AJ, Weiss Smith S, Baer MR, Ke X, Bierenbaum JM, Hendrick F, et al. Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts). 2010;116(21):3815.
2. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmaco Economics. 2005;23(5):505-14.
3. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005;97(7):489-98.
4. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimu-lating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532-42.
5. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708-14.
6. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythro -poiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-15.
7. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stim-ulating agents for anemia related to cancer: a meta-analysis. Cmaj. 2009;180(11):E62-71.
8. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9): 584-90.
9. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chron-ic kidney disease treated with erythropoi-etin: a meta-analysis. Lancet. 2007;369 (9559):381-8.
10. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965-76.
11. Food and Drug Administration. Oncologic Drugs Advisory Committee briefing document: Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia associated with Cancer Chemotherapy. http://www.fda.gov/ ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf. Accessed February 12, 2010.
12. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114 (12):2393-400.
13. Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodys-plastic syndromes. Br J Haematol. 2008; 142(3):379-93.
14. Niazy MN, Neyyarapally TI, Chattopadhyay A. Erythropoietin-induced deep vein thrombosis in myelodysplastic syndrome. J Assoc Physicians India. 2008; 56:195-6.
15. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalido-mide in combination with darbepoietin-alpha. Br J Haematol. 2003;121(1):101-3.
16. Yang X, Brandenburg NA, Freeman J, Salomon ML, Zeldis JB, Knight RD, et al. Venous thromboembolism in myelodys-plastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009;29(3):161-71.
17. Brandenburg NA, Weiss L, Bwire R, Schmidt M, Knight R, List AF. Venous thromboembolism in patients with myelodysplastic syndrome treated with lenaliomide: Incidence and risk factors.Presented at: 44th American Society of Clinical Oncology (ASCO) Annual Meeting: May 30-June 3, 2008; Chicago, IL. Abstract 7084;2008.
18. National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database. http://healthservices.cancer.gov/seer-medicare/.
19. National Cancer Institute. SEER-Medicare: How the SEER & Medicare Data are Linked. http://healthservices.cancer.gov/seer-medicare/overview/linked.html. Accessed September 3, 2011.
20. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
21. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009;18(1):53-65.
22. Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007;12(10):1264-73.
23. Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analy-sis. Ann Hematol. 2008;87(7):527-36.
24. Reynolds MW, Shibata A, Zhao S, Jones N, Fahrbach K, Goodnough LT. Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin. 2008;24(2):497-505.
25. National Comprehensive Cancer Network. NCCN clinical practice guidselines in oncology: cancer- and chemotherapy-induced anemia (version 2.2011) http://www.nccn.org/professionals/physi-cian_gls/pdf/anemia.pdf. Accessed May 27, 2011.
26. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodys-plastic syndrome. J Clin Oncol. 2008;26 (21):3607-13.